Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Gevaert, Philippe; Bruaene, Nicholas Van; Cattaert, Tom; Steen, Kristel Van; Zele, Thibaut Van; Acke, Frederic; Ruyck, Natalie De; Blomme, Katrien; Sousa, Ana R.; Marshall, Richard P.; Bachert, Claus

doi:10.1016/j.jaci.2011.07.056

Cited by 563 publications

(531 citation statements)

References 29 publications

Supporting

Mentioning

495

Contrasting

Unclassified

Order By: Relevance

“…Inflammatory endotypes might be of importance for the prognosis of comorbid asthma development or disease recurrence after surgery 12 . As recent monoclonal antibody approaches such as omalizumab 34 , mepolizumab 35 or dupilumab target specific cytokines or pathways, it is expected that an approach based on biomarker-defined clusters would identify responders to these drugs. Nasal levels of IL-5 for example were found to predict responders to reslizumab, an anti-IL5 monoclonal antibody 36 .…”

Section: Discussionmentioning

confidence: 99%

Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers

Tomassen

Vandeplas

Zele

et al. 2016

Journal of Allergy and Clinical Immunology

Self Cite

898

934

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers

Tomassen

Vandeplas

Zele

et al. 2016

Journal of Allergy and Clinical Immunology

Self Cite

898

934

View full text Add to dashboard Cite

show abstract

“…Six studies fulfilled the inclusion criteria (18)(19)(20)(21)(22)(23) . Αll studies were RCTs and were published between 2006 and 2017.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Three of the studies were single-site (19)(20)(21) while the other three were multisite (18,22,23) . Subjects were randomized to receive: anti-IL5 therapy with reslizumab (18) or mepolizumab (20,23) in three studies, anti-IgE therapy with omalizumab in two studies (19,21) and anti-IL-4Rα therapy with dupilumab in the last RCT (22) . The characteristics of the six included studies as well as baseline demographic and clinical characteristics of the patients are presented in Table 2 and 3.…”

Section: Study Characteristicsmentioning

confidence: 99%

Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review

Tsetsos

Goudakos

Daskalakis

et al. 2018

Rhin

View full text Add to dashboard Cite

Background: Μonoclonal antibodies have been proposed as a novel therapy in patients suffering from chronic rhinosinusitis with nasal polyposis (CRSwNP). The purpose of this systematic review was to evaluate their efficacy and safety.Methodology: A literature search was performed in MEDLINE, Web of Science, the Cochrane Library and multiple trial registries followed by extensive hand-searching for the identification of relevant studies. Only randomized controlled trials (RCTs) comparing the use of monoclonal antibodies with placebo or another therapy in adult patients with CRSwNP were included.Results: Anti-immunoglobin E (IgE) therapy with omalizumab was assessed in two studies, anti-interleukin (IL)-5 therapy in three studies (1 reslizumab, 2 mepolizumab) and finally anti-IL-4 and anti-IL-13 therapy in only one. With the exception of one study, biologic therapy was proved to be effective in reducing total nasal endoscopic polyp score (TPS) in treatment as compared to placebo groups. Monoclonal antibodies brought about improvement in several other outcomes, such as opacification in computed tomography (CT), quality of life measures, nasal airflow, olfaction and type 2 helper T-cell (Th2) associated biomarkers. Overall, the use of these agents was deemed safe and well-tolerated.Conclusions: This is the first systematic review showing encouraging results for the use of all three main categories of monoclonal antibodies in CRSwNP patients and highlights the need for further well-designed and with larger sample sizes RCTs.

show abstract

“…Mepolizumab, which blocks the binding of IL-5 to eosinophils, has shown a beneficial effect on severe eosinophilic asthma [103,104], hypereosinophilic syndrome [105], and severe eosinophilic polyposis [106] in adults. Pitrakinra, a recombinant IL-4 variant that competitively binds the IL-4Ra receptor, inhibiting the binding of both IL-4 and IL-13, substantially diminished asthma symptoms during the late-phase asthmatic response after allergen challenge [107].…”

Section: Other Interventionsmentioning

confidence: 99%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of 'united airways disease' or 'respiratory allergy', implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the 'atopic march'. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

show abstract

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Cited by 563 publications

References 29 publications

Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers

Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers

Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

Contact Info

Product

Resources

About